Erken Başlangıçlı ve Ailesel Mide Kanseri Kayıt Sistemi

Sade dilde özet

Bu çalışma, erken başlangıçlı ve ailesel mide kanseri (gastric cancer) olan kişileri ve ailelerini izleyen bir kayıt sistemidir. Mide veya mide-yemek borusu birleşim yeri kanseri olan kişiler ve yüksek riskli aile bireyleri dahil edilir. Faz uygulanmayan gözlemsel bir kayıttır ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

N/A

Durum

Tamamlandı

Sponsor

Memorial Sloan Kettering Cancer Center

Müdahale

questionnaires

Başlangıç

13.12.2005

Tahmini bitiş

30.09.2024

Ülkeler

United States, Nigeria

İlgili genler

Merkezler

• Los Angeles, United States
• Basking Ridge, United States
• Middletown, United States
• Commack, United States
• East White Plains, United States
• Jamaica, United States
• New York, United States
• New York, United States
• Rockville Centre, United States
• Ile-Ife, Nigeria

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

Patient/Relative Cohort:

Must meet one or more criteria below:

1. A person with a diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma confirmed at the treating institution.
2. A person without gastric or GEJ adenocarcinoma who has or had a first degree relative eligible for a High Risk Genetic sub-group (EOGC/FGC).

   1. Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.
   2. Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.
3. A person without gastric or GEJ adenocarcinoma who has a personal family history of a genetic mutation associated with the development of gastric or GEJ adenocarcinoma (i.e. family history of CDH1 mutation).

II. Must be willing to provide a blood sample for germline DNA. These individuals will sign the "Patient/Relative Consent". Following enrollment, we will assign individuals to the appropriate High Genetic Risk or Low Genetic Risk groups based on the age of diagnosis and their family history.

Subject Exclusion Criteria

Patients are ineligible for the study if they:

* Have any condition, which in the opinion of the primary MSK clinician or investigators precludes their ability to provide informed consent.
* Relatives of patients that are not eligible for the High Genetic Risk Cohorts who are less than 18 years of age are excluded.
* Relatives of patients eligible for the High Genetic Risk Cohorts who do not have a proband available to join the study are excluded. (Unless there is a known CDH1 mutation in the family).